本文選題：棕櫚酸帕利哌酮　切入點(diǎn)：利培酮　出處：《中國(guó)新藥雜志》2014年08期

【摘要】：目的:研究棕櫚酸帕利哌酮對(duì)少年精神分裂癥的療效、耐受性、安全性及對(duì)社會(huì)功能的影響。方法:入組147例患者,均符合《美國(guó)精神障礙診斷與統(tǒng)計(jì)手冊(cè)》第4版中精神分裂癥診斷標(biāo)準(zhǔn),且年齡為16~18歲,按隨機(jī)數(shù)字表法分為棕櫚酸帕利哌酮組67例和利培酮組80例。棕櫚酸帕利哌酮組治療劑量100~150 mg·mL-1,利培酮組治療劑量4~6 mg·d-1,觀察期為12周。于基線、治療2,4,8,12周末采用陽(yáng)性與陰性癥狀量表(PANSS)和個(gè)人和社會(huì)功能量表(PSP)分別評(píng)價(jià)有效性和社會(huì)功能,并用臨床總體印象量表改善項(xiàng)目(CGI-I)評(píng)價(jià)其療效,比較治療后與基線的差異,包括每組前后和組間差異。記錄相關(guān)不良反應(yīng),對(duì)147例患者進(jìn)行安全性分析。結(jié)果:共有102例患者完成研究,棕櫚酸帕利哌酮組47例,利培酮組55例。兩組在治療第12周末的PANSS陽(yáng)性癥狀、陰性癥狀分及總分較基線有顯著降低,CGI-I評(píng)分較基線有明顯改善,但兩組組間相比差異無(wú)統(tǒng)計(jì)學(xué)意義。兩組PSP總分改善隨時(shí)間變化較基線有改善,棕櫚酸帕利哌酮組在第2周[(40.68±5.58)vs(32.38±9.24),P0.01],第4周[(45.14±5.14)vs(40.24±9.37),P0.05],第12周[(66.73±10.38)vs(55.48±9.86),P0.01)]較利培酮組改善更為明顯。棕櫚酸帕利哌酮組不良反應(yīng)發(fā)生率小于利培酮組(17.3%vs 42%,P=0.001)。結(jié)論:棕櫚酸帕利哌酮能有效改善少年精神分裂癥患者的精神癥狀和社會(huì)功能,減少藥物不良反應(yīng),耐受性好。
[Abstract]:Objective: to study the efficacy, tolerance, safety and social function of palipiperidone palmitate in the treatment of juvenile schizophrenia. In accordance with the diagnostic criteria for schizophrenia in the 4th edition of the American Handbook for the diagnosis and Statistics of Mental Disorders, and aged 1618 years, According to the random number table method, 67 cases of palipiperidone palmitate group and 80 cases of risperidone group were divided into two groups: paliperidone palmitate group (100mg / ml), risperidone group (4mg / d) and risperidone group (4mg / d) for 12 weeks. The efficacy and social function were evaluated by using the positive and negative symptom scale (PANSS) and the personal and social function scale (PSPP) at the end of 12 weeks of treatment. The efficacy was evaluated with the clinical general impression improvement item (CGI-I), and the difference between the treatment and baseline was compared. Safety analysis was performed in 147 patients. Results: 102 patients completed the study, 47 in the palmitic acid group, 47 in the palmitate group. There were 55 cases in risperidone group. At the end of the 12th week of treatment, the scores of negative symptoms and total scores of PANSS in both groups were significantly lower than that of baseline, and the scores of CGI-I were significantly improved compared with baseline. However, there was no significant difference between the two groups. The improvement of the total score of PSP in the two groups over time was better than that in the baseline. In the second week [40.68 鹵5.58)vs(32.38 鹵9.24P0.01], in the 4th week [45.14 鹵5.14)vs(40.24 鹵9.37P0.01], in the 12th week [66.73 鹵9.86P0.01], the improvement was more obvious in the palmitate group than in the risperidone group. The incidence of adverse reactions in the palipiperidone palmitate group was lower than that in the risperidone group. Conclusion: palmitic acid paliperidone can effectively correct P0.01.Conclusion: Pariperidone palmitate is effective. Mental symptoms and social functions of juvenile schizophrenic patients, Reduce adverse drug reactions, good tolerance.
【作者單位】： 華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬精神衛(wèi)生中心;武漢市精神衛(wèi)生中心;
【分類號(hào)】：R749.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 王冬梅;;兒童青少年精神分裂癥藥物治療的臨床研究進(jìn)展[J];國(guó)際精神病學(xué)雜志;2012年03期

2 何燕玲,張明園;陽(yáng)性和陰性綜合征量表(PANSS)及其應(yīng)用[J];臨床精神醫(yī)學(xué)雜志;1997年06期

3 高志勤;余海鷹;崔雪蓮;金梅;邱旭萍;;低頻重復(fù)經(jīng)顱磁刺激治療精神分裂癥慢性幻聽(tīng)的療效及隨訪研究[J];精神醫(yī)學(xué)雜志;2009年04期

4 孫凌;周天紅;雷彤;;帕利哌酮緩釋片治療兒童期首發(fā)精神分裂癥37例的療效及安全性[J];中國(guó)新藥雜志;2011年09期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 錢文勝;;阿立哌唑與奧氮平對(duì)女性精神分裂癥患者治療的對(duì)照研究[J];兵團(tuán)醫(yī)學(xué);2009年01期

2 王大芬;王興容;;奎硫平與利培酮治療精神分裂癥的比較xO究[J];重慶醫(yī)學(xué);2006年18期

3 展玉蘭;慢性精神分裂癥患者院內(nèi)康復(fù)訓(xùn)練措施探究[J];當(dāng)代護(hù)士(學(xué)術(shù)版);2004年12期

4 李雪麗;;齊拉西酮長(zhǎng)期應(yīng)用于老年精神分裂癥患者對(duì)其血栓病變發(fā)病率的影響分析[J];當(dāng)代醫(yī)學(xué);2011年17期

5 陳小周;紀(jì)家武;黃少雅;陳濤;;齊哌西酮治療精神分裂癥的臨床應(yīng)用[J];福建醫(yī)藥雜志;2007年02期

6 蘇e，

本文編號(hào)：1685714